Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $3.02
    -0.03 (-0.98%)

    Market Cap: $257.17M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Protalix Biotherapeutics Inc (PLX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Protalix Biotherapeutics (PLX) trades at 12.1x trailing earnings and 2.9x sales. Its P/S of 2.9x is above its 5-year median of 1.8x. Its forward P/E is 61.0x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 80.2% lower over the next year. Its free cash flow yield is 6.2%.

    MultipleValue
    P/E (trailing)12.1x
    Forward P/E61.0x
    Price to sales2.9x
    Price to book3.0x
    EV/EBITDA8.0x
    Price to FCF16.1x
    EV/FCF14.7x
    PEGN/A
    FCF yield6.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 45.0% above 2.0x.

    MultipleCurrent5-year median10-year median
    P/S2.9x1.8x2.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 111 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 0.9x in 2019 to 214.3x in 2018.

    Year endPriceP/EP/SP/B
    2025$1.80N/A2.7x2.9x
    2024$1.8862.7x2.7x3.5x
    2023$1.7829.7x1.8x3.9x
    2022$1.37N/A1.4xN/A
    2021$0.83N/A0.9xN/A
    2020$3.63N/A1.9xN/A
    2019$3.28N/A0.9xN/A
    2018$3.11N/A214.3xN/A
    2017$6.61N/AN/AN/A
    2016$4.45N/A1.9xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PLX

    What is PLX's forward P/E ratio?

    Protalix Biotherapeutics has a forward P/E ratio of 61.0x.

    Is PLX stock overvalued?

    GNG's valuation label for PLX is Fairly valued.

    What is PLX's price to sales ratio?

    Protalix Biotherapeutics has a price to sales ratio of 2.9x.